KRT18 and infection: Dosing regimens and drug concentrations were chosen on the basis of preliminary studies performed in a mouse model of influenza A virus infection, which showed antiviral efficacy at 7.2 mg kg−1 (data not shown), and also on the basis of the solubility of N-0385 and on the knowledge that K18-hACE2 mice typically survive 6 to 8 days post-infection (dpi) with SARS-CoV-239.